Jump to Navigation

Facebook Connect

User login

Dyslipidemia: New Challenges and Emerging Options in Lowering CVD Risk- Activity 2: The PCSK9 Pathway and Other Emerging Options

New 3-part online continuing education eCourse exploring the changing landscape of dyslipidemia management.  Experts in lipidology examine treatment guidelines, strategies for CV risk reduction, and the value of collaborative care for patients.



Program Description

Reduction of low-density lipoprotein cholesterol (LDL-C) is widely recognized as the most effective intervention for reducing cardiovascular risk, and robust evidence supports aggressive use of statins to lower LDL-C. However, some patients cannot achieve adequate reduction in their LDL-C levels with statins, even with the addition of other classes of antidyslipidemic agents. This interactive 3-part CME/CPE eCourse convenes 3 experts in lipidology to discuss current options and emerging therapies for lowering LDL-C. In this activity, the emphasis is on PCSK9 inhibitors, a new class of cholesterol-lowering drugs that are self-injected once or twice a month. These agents reduce LDL-C levels dramatically—often to levels never seen before.

Click her to launch this activity

Accreditation Information

Content Domain
This activity falls under the following content domain(s):

  • 6.8 Lifestyle Management and CVD Prevention

Learning Objectives
This activity teaches to the following learning objective(s):

  1. Establish a collaborative care practice model to recognize at-risk patients for statin-induced myopathy and myositis and to foster adherence to lipid-lowering medications through monitoring and patient engagement
  2. Examine current and emerging options for lowering elevated cholesterol when individualizing treatment strategies for patients with statin intolerance

by Dr. Radut.